Recombinant multi-species EGFL6 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine EGFL6 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
This gene encodes a member of the epidermal growth factor (EGF) repeat superfamily. Members of this superfamily are characterized by the presence of EGF-like repeats and are often involved in the regulation of cell cycle, proliferation, and developmental processes. The gene product contains a signal peptide, suggesting that it is secreted; an EGF repeat region consisting of 4 complete EGF-like repeats and 1 partial EGF-like repeat, 3 of which have a calcium-binding consensus sequence; an arg-gly-asp integrin association motif; and a MAM domain, which is believed to have an adhesive function. This gene is expressed early during development, and its expression has been detected in lung and meningioma tumors. [provided by RefSeq, Jul 2008]
The Alternative Names of target: EGF-like protein 6,EGFL6,Egfl6,Epidermal growth factor-like protein 6,MAEG,MAM and EGF domains-containing gene protein,Maeg,W80

Target products collectionGo to EGFL6 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-T28620-Ag-1/ GM-Tg-hg-T28620-Ag-2 Human EGFL6 protein Human
GM-Tg-rg-T28620-Ag-1/ GM-Tg-rg-T28620-Ag-2 Rat EGFL6 protein Rat
GM-Tg-mg-T28620-Ag-1/ GM-Tg-mg-T28620-Ag-2 Mouse EGFL6 protein Mouse
GM-Tg-cynog-T28620-Ag-1/ GM-Tg-cynog-T28620-Ag-2 Cynomolgus/Rhesus macaque EGFL6 protein Cynomolgus/ Rhesus macaque
GM-Tg-felg-T28620-Ag-1/ GM-Tg-felg-T28620-Ag-2 Feline EGFL6 protein Feline
GM-Tg-cang-T28620-Ag-1/ GM-Tg-cang-T28620-Ag-2 Canine EGFL6 protein Canine
GM-Tg-bovg-T28620-Ag-1/ GM-Tg-bovg-T28620-Ag-2 Bovine EGFL6 protein Bovine
GM-Tg-equg-T28620-Ag-1/ GM-Tg-equg-T28620-Ag-2 Equine EGFL6 protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-T28620-Ag-1/ GM-Tg-hg-T28620-Ag-2; GM-Tg-rg-T28620-Ag-1/ GM-Tg-rg-T28620-Ag-2;
GM-Tg-mg-T28620-Ag-1/ GM-Tg-mg-T28620-Ag-2; GM-Tg-cynog-T28620-Ag-1/ GM-Tg-cynog-T28620-Ag-2;
GM-Tg-felg-T28620-Ag-1/ GM-Tg-felg-T28620-Ag-2; GM-Tg-cang-T28620-Ag-1/ GM-Tg-cang-T28620-Ag-2;
GM-Tg-bovg-T28620-Ag-1/ GM-Tg-bovg-T28620-Ag-2; GM-Tg-equg-T28620-Ag-1/ GM-Tg-equg-T28620-Ag-2
Products Name EGFL6 protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name EGFL6
Protein Sub-location Secreted Protein/Potential Cytokines
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine EGFL6 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.